| UC Davis |
|
UC Davis |
Cancer - Lymphoma (HIV-Related) |
Gene Therapy in Treating Patients with Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant |
Recruiting |
|
| City of Hope |
|
City of Hope |
Cancer - Lymphoma (AIDS-Related) |
Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma |
Active, not recruiting |
|
| UCSD |
|
Fate Therapeutics |
Solid tumors |
FATE-NK100 as Monotherapy and in Combination with Monoclonal Antibody in Subjects with Advanced Solid Tumors |
No longer active |
|
| UCSD |
|
UCSD |
Cancer - Leukemia |
Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 |
No longer active |
|
| City of Hope |
|
Novartis Pharmaceuticals |
Cancer - Lymphona |
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA) |
Recruiting |
|
| City of Hope |
|
Kite Pharma |
Cancer - Lymphoma |
Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12) |
Recruiting |
|
| UCLA |
|
Orchard Therapeutics |
Severe Combined Immunodeficiency (SCID) |
Efficacy and Safety of a Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With EFS Lentiviral Vector Encoding for Human ADA Gene in Subjects With ADA Deficiency Severe Combined Immunodeficiency |
Active, not recruiting |
|
| City of Hope |
|
Sangamo Therapeutics |
Hemophilia A |
Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A |
Recruiting |
|
| City of Hope |
|
Precision BioSciences, Inc. |
Cancer - Lymphoma |
Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL |
Recruiting |
|
| UCSD |
|
Asterias Biotherapeutics |
Spinal Cord Injury |
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury |
No longer active |
|
| UCI |
|
Cartesian Therapeutics |
MYASTHENIA GRAVIS (MG) |
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) |
Recruiting |
|
| UCSD |
|
Persimmune, Inc. |
Cancer - Blood |
Collection of Bone Marrow, Peripheral Blood (PB), Epithelial Tissue, and Saliva Samples From Patients With Myelodysplastic Syndromes (MDS) to Identify MDS-Specific Antigens |
No longer active |
|
| UC Davis |
|
UC Davis |
Eye - Retinopathy |
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy |
Recruiting |
|
| UCSD |
|
Calibr |
Relapsed/Refractory B-cell Lymphomas |
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies |
No longer active |
|
| UCSD |
|
UCSD/Oncternal |
chronic lymphocytic leukemia |
Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax |
Active, not recruiting |
|
| UC Davis |
|
Medeor Therapuetics |
Kidney Transplant |
Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants |
No longer active |
|
| City of Hope |
|
City of Hope |
Cancer - Brain |
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas |
Recruiting |
|
| UCLA |
|
UCLA |
Severe Combined Immunodeficiency (SCID) |
Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID) |
Active, not recruiting |
|
| UC Davis |
|
UC Davis |
Cancer - Tongue Dysphagia |
Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia |
Recruiting |
|
| UCI & UCSD & UC Davis |
|
Aivita Biomedical |
Cancer - Brain |
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma |
Active, not recruiting |
|
| UCSD |
|
Aivita |
Ovarian and Fallopian Tube Carcinoma |
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas |
Active, not recruiting |
|
| City of Hope |
|
Sangamo Therapeutics |
Hemophilia B |
Ascending Dose Study of Genome Editing by the Zinc Finger Protein (ZFP) Therapeutic SB-FIX in Subjects With Severe Hemophilia B |
Recruiting |
|
| City of Hope |
|
Children’s Hospital Los Angeles |
Infection After Stem Cell Transplant |
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution |
Recruiting |
|
| City of Hope |
|
City of Hope |
Cancer - Lymphoma |
Angiocrine: HuVEC infusion post HCT in lymphoma (Budde) |
Active, not recruiting |
|
| UC Davis |
|
Atara Bio |
Hematologic Malignancies |
An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases |
Recruiting |
|
| City of Hope |
|
Juno Therapeutics |
Cancer - Lymphoma |
An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004) |
Recruiting |
|
| UC Davis |
|
Autolus |
Acute Lymphoblastic Leukaemia |
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia |
Active, not recruiting |
|
| UC Davis & UCSD |
|
Viacyte |
Type 1 diabetes |
An Open-Label, First-in-Human, Study Evaluating the Safety, Tolerability, and Efficacy of VC-02 Combination Product in Subjects with Type 1 Diabetes Mellitus and Hypoglycemia Unawareness |
No longer active |
|
| UC Davis |
|
Eureka Therapeutics |
Hepatocellular Carcinoma |
An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140203 T Cells and Determine the Recommended Phase II Dose (RP2D) in Adults With Advanced Hepatocellular Carcinoma (HCC) |
Recruiting |
|
| City of Hope |
|
Celgene |
Cancer - Lymphoma |
An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM) |
Recruiting |
|
| UCSF |
|
UCSF |
Graft versus Host Disease (GvHD) |
An Expanded Access Study of Using the CLINIMACS® Device for Alpha/Beta T-Cell Depletion in Stem Cell Transplant Recipients |
Recruiting |
|
| UCI & UC Davis |
|
Humacyte |
Kidney Failure |
An Assessment of Humacyte’s Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY) |
No longer active |
|
| UCSF |
|
Stanford University |
Severe Combined Innunodeficiency (SCID) |
AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study for SCID Patients |
Recruiting |
|
| UCLA |
Scott Nowicki, MD, PhD
|
UCLA |
Cancer - Solid Tumors |
Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies |
No longer active |
|
| City of Hope |
|
City of Hope |
Neurodegenerative Disorder |
Acquisition of Skin Biopsy Samples from Healthy Volunteers and Patients Diagnosed with X-Linked Adrenoleukodystrophy (ALD), Canavan Disease (CD) and other Inherited Leukodystrophies |
Recruiting |
|
| UCSF & UCLA |
|
Sangamo Therapeutics |
Blood Disorder - Beta-Thalassemia |
A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) |
No longer active |
|
| UCSD & City of Hope |
|
UCSD |
Cancer - Leukemia |
A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies |
Active, not recruiting |
|
| City of Hope |
|
Janssen Research & Development, LLC. |
Cancer - Myeloma |
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1) |
Recruiting |
|
| UCSF |
|
PACT Pharma |
Cancer – Solid Tumor |
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors |
No longer active |
|
| UC Davis |
|
Orca Biosystems Inc. |
Hematologic Malignancies |
A Study of Engineered Donor Grafts (TregGraft) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies |
Recruiting |
|
| UC Davis |
|
Capricor Therapeutics |
Muscle - Duchenne Muscular Dystrophy |
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2) |
No longer active |
|
| UCSF |
|
bluebird bio |
Sickle Cell Disease |
A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease |
No longer active |
|
| UC Davis |
|
Kite Pharma |
Advanced Cancer |
A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers |
No longer active |
|
| City of Hope |
|
Kite Pharma |
Cancer - Lymphoma |
A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6) |
No longer active |
|
| UCSD |
|
Viacyte |
Diabetes - Type 1 |
A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness |
No longer active |
|
| UCSD |
|
Viacyte |
Diabetes - Type 1 |
A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus |
No longer active |
|
| UCSF |
|
Talaris |
Transplanted Organ Rejection |
A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation (FREEDOM-1) |
No longer active |
|
| UCI |
|
ReNeuron Limited |
Stroke |
A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects with Disability Following an Ischemic Stroke (PISCES III) |
No longer active |
|
| UCI |
|
Pluristem Ltd. |
Intubated COVID-19 patients |
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19 |
No longer active |
|
| UC Davis |
|
Capricor Therapeutics |
COVID |
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Delivery of CAP-1002 in Patients with Severe COVID-19 |
No longer active |
|
